{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009670","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.515266+00:00","generated_at":"2026-06-25T18:28:29.436305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22","bullets":["Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.","Cash, equivalents & investments $301.2M at March 31, 2022 vs $319.7M at December 31, 2021.","Topline ACT-AD Phase 2 data in mild-to-moderate Alzheimer's expected by end of Q2 2022.","LIFT-AD Phase 3 enrollment target increased to ~420 patients; completion expected in Q3 2022.","Dosed first patient in SHAPE Phase 2 trial for Parkinson's disease dementia and Dementia with Lewy bodies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009670","json":"https://secwatch.observer/filing/0000950170-22-009670.json","markdown":"https://secwatch.observer/filing/0000950170-22-009670.md","text":"https://secwatch.observer/filing/0000950170-22-009670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/0000950170-22-009670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/atha-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:28:29.436305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}